Therapeutic hypothermia for acute stroke

Patrick D. Lyden, Derk Krieger, Midori Yenari, W. Dalton Dietrich

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Hypothermia is the most potent neuroprotective therapy available. Clinical use of hypothermia is limited by technology and homeostatic mechanisms that maintain core body temperature. Recent advances in intravascular cooling catheters and successful trials of hypothermia for cardiac arrest revivified interest in hypothermia for stroke, resulting in Phase 1 clinical trials and plans for further development. Given the recent spate of neuroprotective therapy failures, we sought to clarify whether clinical trials of therapeutic hypothermia should be mounted in stroke patients. We reviewed the preclinical and early clinical trials of hypothermia for a variety of indications, the putative mechanisms for neuroprotection with hypothermia, and offer several hypotheses that remain to be tested in clinical trials. Therapeutic hypothermia is promising, but further Phase 1 and Phase 2 development efforts are needed to ensure that cooling of stroke patients is safe, before definitive efficacy trials.

Original languageEnglish
Pages (from-to)9-19
Number of pages11
JournalInternational Journal of Stroke
Volume1
Issue number1
DOIs
StatePublished - Feb 1 2006

Fingerprint

Induced Hypothermia
Hypothermia
Stroke
Clinical Trials
Clinical Trials, Phase I
Heart Arrest
Body Temperature
Catheters
Technology
Therapeutics

ASJC Scopus subject areas

  • Neurology

Cite this

Therapeutic hypothermia for acute stroke. / Lyden, Patrick D.; Krieger, Derk; Yenari, Midori; Dalton Dietrich, W.

In: International Journal of Stroke, Vol. 1, No. 1, 01.02.2006, p. 9-19.

Research output: Contribution to journalArticle

Lyden, Patrick D. ; Krieger, Derk ; Yenari, Midori ; Dalton Dietrich, W. / Therapeutic hypothermia for acute stroke. In: International Journal of Stroke. 2006 ; Vol. 1, No. 1. pp. 9-19.
@article{9aa0c6cddb9f4ace953c07667c141464,
title = "Therapeutic hypothermia for acute stroke",
abstract = "Hypothermia is the most potent neuroprotective therapy available. Clinical use of hypothermia is limited by technology and homeostatic mechanisms that maintain core body temperature. Recent advances in intravascular cooling catheters and successful trials of hypothermia for cardiac arrest revivified interest in hypothermia for stroke, resulting in Phase 1 clinical trials and plans for further development. Given the recent spate of neuroprotective therapy failures, we sought to clarify whether clinical trials of therapeutic hypothermia should be mounted in stroke patients. We reviewed the preclinical and early clinical trials of hypothermia for a variety of indications, the putative mechanisms for neuroprotection with hypothermia, and offer several hypotheses that remain to be tested in clinical trials. Therapeutic hypothermia is promising, but further Phase 1 and Phase 2 development efforts are needed to ensure that cooling of stroke patients is safe, before definitive efficacy trials.",
author = "Lyden, {Patrick D.} and Derk Krieger and Midori Yenari and {Dalton Dietrich}, W.",
year = "2006",
month = "2",
day = "1",
doi = "10.1111/j.1747-4949.2005.00011.x",
language = "English",
volume = "1",
pages = "9--19",
journal = "International Journal of Stroke",
issn = "1747-4930",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Therapeutic hypothermia for acute stroke

AU - Lyden, Patrick D.

AU - Krieger, Derk

AU - Yenari, Midori

AU - Dalton Dietrich, W.

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Hypothermia is the most potent neuroprotective therapy available. Clinical use of hypothermia is limited by technology and homeostatic mechanisms that maintain core body temperature. Recent advances in intravascular cooling catheters and successful trials of hypothermia for cardiac arrest revivified interest in hypothermia for stroke, resulting in Phase 1 clinical trials and plans for further development. Given the recent spate of neuroprotective therapy failures, we sought to clarify whether clinical trials of therapeutic hypothermia should be mounted in stroke patients. We reviewed the preclinical and early clinical trials of hypothermia for a variety of indications, the putative mechanisms for neuroprotection with hypothermia, and offer several hypotheses that remain to be tested in clinical trials. Therapeutic hypothermia is promising, but further Phase 1 and Phase 2 development efforts are needed to ensure that cooling of stroke patients is safe, before definitive efficacy trials.

AB - Hypothermia is the most potent neuroprotective therapy available. Clinical use of hypothermia is limited by technology and homeostatic mechanisms that maintain core body temperature. Recent advances in intravascular cooling catheters and successful trials of hypothermia for cardiac arrest revivified interest in hypothermia for stroke, resulting in Phase 1 clinical trials and plans for further development. Given the recent spate of neuroprotective therapy failures, we sought to clarify whether clinical trials of therapeutic hypothermia should be mounted in stroke patients. We reviewed the preclinical and early clinical trials of hypothermia for a variety of indications, the putative mechanisms for neuroprotection with hypothermia, and offer several hypotheses that remain to be tested in clinical trials. Therapeutic hypothermia is promising, but further Phase 1 and Phase 2 development efforts are needed to ensure that cooling of stroke patients is safe, before definitive efficacy trials.

UR - http://www.scopus.com/inward/record.url?scp=33646703742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646703742&partnerID=8YFLogxK

U2 - 10.1111/j.1747-4949.2005.00011.x

DO - 10.1111/j.1747-4949.2005.00011.x

M3 - Article

C2 - 18706063

AN - SCOPUS:33646703742

VL - 1

SP - 9

EP - 19

JO - International Journal of Stroke

JF - International Journal of Stroke

SN - 1747-4930

IS - 1

ER -